[PS1] Presidential Session 1
【E】

[PS1-5] IMpower010: results from Asian patients in a Phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC

^○Hirotsugu Kenmotsu¹, Caicun Zhou², Nasser Altorki³, Enriqueta Felip⁴, Eric Vallieres⁵, Shunichi Sugawara⁶, Hiroshi Sakai⁷, Haruhiro Saito⁸, Min Tao⁹, Koji Kawaguchi¹⁰, Yunpeng Liu¹¹, Chong-Jen Yu¹², Qiong Wu¹³, Huang Lin¹³, Fan Wu¹³, Elizabeth Bennett¹⁴, Virginia Mcnally¹⁵, Barbara Gitlitz¹⁴, Heather Wakelee¹⁶ (1.Division of Thoracic Oncology, 2.Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China, 3.NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA, 4.Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, 5.Swedish Cancer Institute, Seattle, WA, USA, 6.Sendai Kousei Hospital, Miyagi, Japan, 7.Saitama Cancer Center, Saitama, Japan, 8.Kanagawa Cancer Center, Yokohama, Japan, 9.The First Affiliated Hospital of Soochow University, Jiangsu, China, 10.Mie University Graduate School of Medicine, Mie, Japan, 11.First Hospital, China Medical University, Shenyang, China, 12.National Taiwan University, Taipei City, Taiwan, 13.Roche (China) Holding Ltd, Shanghai, China, 14.Genentech Inc, South San Francisco, CA, USA, 15.Roche Products Ltd, Welwyn Garden City, United Kingdom, 16.Stanford University School of Medicine, Stanford Cancer Institute, Stanford, CA, USA)